Clare Das

Predicting Survival in Pulmonary Arterial Hypertension

Borderline Mean Pulmonary Artery Pressure in Patients With Systemic Sclerosis: Transpulmonary Gradient Predicts Risk of Developing Pulmonary Hypertension

A RASSF1A-HIF1α loop drives Warburg effect in cancer and pulmonary hypertension

Haemodynamic definitions and updated clinical classification of pulmonary hypertension

Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study

Tadalafil Therapy for Pulmonary Arterial Hypertension

American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis

Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study

Survival of Chinese Patients With Pulmonary Arterial Hypertension in the Modern Treatment Era

Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) – A subgroup analysis of the ARIES-E clinical trial

Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension

Definitions and Diagnosis of Pulmonary Hypertension

Antithrombotic Therapy for VTE Disease

A global view of pulmonary hypertension

Survival in pulmonary hypertension in Spain: insights from the Spanish registry

Updated Clinical Classification of Pulmonary Hypertension

Pulmonary Hypertension in Chronic Lung Diseases

Leflunomide-Induced Pulmonary Hypertension in a Young Woman with Rheumatoid Arthritis: A Case Report

Development of a provisional core set of response measures for clinical trials of systemic sclerosis

Systemic sclerosis

Role of NT-proBNP and 6MWD in chronic thromboembolic pulmonary hypertension

Early detection of pulmonary arterial hypertension

Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: Results from an international prospective registry

Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients

Antithrombotic Therapy for VTE Disease

Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension

Diagnosis and Assessment of Pulmonary Arterial Hypertension

Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: Impact of interstitial lung disease

Diagnosis, Assessment, and Treatment of Non-Pulmonary Arterial Hypertension Pulmonary Hypertension

Updated Clinical Classification of Pulmonary Hypertension

Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), Physician‐ and Patient‐Rated Global Assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0, Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) (Mahler's Index), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), and Raynaud's Condition Score (RCS)

Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension

Dobutamine Stress Echocardiography for the Assessment of Pressure-Flow Relationships of the Pulmonary Circulation

Long-term Outcome after Pulmonary Endarterectomy

Pulmonary Thromboendarterectomy for Chronic Thromboembolic Pulmonary Hypertension : A Systematic Review

Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension

Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension

Survival in systemic sclerosis–pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry

Prognostic and aetiological factors in chronic thromboembolic pulmonary hypertension

Chronic Thromboembolic Pulmonary Hypertension

A consensus document for the selection of lung transplant candidates: 2014—An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation

Chronic thromboembolic pulmonary hypertension

Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography

Brief Report: Effect of ambrisentan treatment on exercise‐induced pulmonary hypertension in systemic sclerosis: A prospective single‐center, open‐label pilot study

Outcomes in Systemic Sclerosis–Related Lung Disease After Lung Transplantation

Prevalence of pulmonary hypertension in hereditary spherocytosis

ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre

A cross-sectional study of the prevalence and associations of iron deficiency in a cohort of patients with chronic obstructive pulmonary disease

Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study

Clinical iron deficiency disturbs normal human responses to hypoxia

Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension

Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension

Chronic Thromboembolic Pulmonary Hypertension

Characteristics and Survival of Anti–U1 RNP Antibody–Positive Patients With Connective Tissue Disease–Associated Pulmonary Arterial Hypertension

ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension

Exercise during cardiac catheterization distinguishes between pulmonary and left ventricular causes of dyspnea in systemic sclerosis patients

Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism

Diagnostic Evaluation and Management of Chronic Thromboembolic Pulmonary Hypertension: A Clinical Practice Guideline

Recommendations for Screening and Detection of Connective Tissue Disease–Associated Pulmonary Arterial Hypertension

Cardiac Biomarkers in Systemic Sclerosis: Contribution of High‐Sensitivity Cardiac Troponin in Addition to N‐Terminal Pro‐Brain Natriuretic Peptide

The responsiveness and validity of the CAMPHOR Utility Index

Connective Tissue Disease–associated Pulmonary Arterial Hypertension in the Modern Treatment Era

Improved Outcomes in Medically and Surgically Treated Chronic Thromboembolic Pulmonary Hypertension

Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension